pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Summary of Representative Published Data on EUS-Guided Ethanol Ablation for Pancreatic Cystic Neoplasms
| Study | No. of patients | Indication (%) |
Size (mm) |
Needle (gauge) | Ablative agent | Complete resolution rate | Session | Adverse events |
|---|---|---|---|---|---|---|---|---|
| Studies that used ethanol for ablation | ||||||||
| Gan et al28 (2005) | 25 | MCN (52), IPMN (16), SCN (12), pseudocyst (12), indeterminate cyst (8) | 19.4 | 22 | 5%–80% ethanol | 35% | 1 ( |
None |
| DeWitt et al25 (2009) | 25 | MCN (40), IPMN (40), SCN (12), PC (8) | 10–41 | 22 | 80% ethanol | 40.9% | 1 ( |
Pancreatitis ( |
| DiMaio et al29 (2011) | 13 | IPMN (100) | 10–32 | 22 | 80% ethanol | 38% | 2 ( |
None |
| Caillol et al31 (2012) | 13 | MCN (100) | 10–50 | NA | 99% ethanol | 85% | 1 ( |
None |
| Gómez et al30 (2016) | 23 | IPMN (66), MCN (17), nonmucinous (17) | 14.9–49.3 | 19, 22 | 0%–79% ethanol | 9% | 1 ( |
Pancreatitis ( |
| Studies that used ethanol and paclitaxel for ablation | ||||||||
| Oh et al3 (2008) | 14 | MCN (14), SCN (21), lymphangioma (21), indeterminate cyst (44) | 17–52 | 22 | 99% ethanol + paclitaxel (3 mg/mL) | 79% | 1 ( |
Pancreatitis ( |
| Oh et al32 (2009) | 10 | MCN (30), SNC (40), indeterminate cyst (30) | 20–68 | 22 | 99% ethanol + paclitaxel (3 mg/mL) | 60% | 1 ( |
Pancreatitis ( |
| Oh et al26 (2011) | 47 | MCN (19), SCN/PC (32), indeterminate (49) | 17–68 | 22 | 99% ethanol + paclitaxel (3 mg/mL) | 62% | 1 ( |
Pancreatitis ( |
| DeWitt et al33 (2014) | 22 | IPMN (55), MCN (27), SCN (18) | 15–43 | 22 | 100% ethanol + paclitaxel (2 mg/mL) | 50% | 1 ( |
Pancreatitis ( |
| Studies that used ethanol, paclitaxel, and gemcitabine for ablation | ||||||||
| Moyer et al27 (2017) | 39 | MCN (23), IPMN (69), indeterminate (8) | 16–42 | 19, 22 | 3 mg/mL paclitaxel + 19 mg/mL gemcitabine with/without 80% ethanol | 64% | Pancreatitis ( |
|
EUS, endoscopic ultrasound; MCN, mucinous cystadenoma; IPMN, intraductal papillary neoplasm; SCN, serous cystadenoma; PC, pseudocyst; NA, not available.
*Presumed diagnosis according to various modalities.
†Mean or range.
‡Abdominal pain was not considered an adverse event.